Physician profile
Ann Macmurray
NPI 1306125448
$2,869.88
in general payments reported to CMS, 2019-2025
19 companies · $634 in 2025
The $634 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $110 · 2023: $602 · 2024: $1,270 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.61 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $547.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $361.68 | 2023-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $319.89 | 2021-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $312.08 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $296.03 | 2023-2025 | |
| Amgen INC. | $263.17 | 2023-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $153.67 | 2023-2025 | Cologuard Collection Kit |
| Gen-Probe Sales & Service, INC. | $145.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.64 | 2023 | |
| Sanofi-Aventis U.S. LLC | $80.25 | 2022-2025 | |
| Abbvie INC. | $75.02 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.00 | 2022 | |
| Daiichi Sankyo INC. | $46.25 | 2021-2024 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $32.65 | 2025 | Austedo Xr |
| Amarin Pharma, INC. | $26.45 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $21.19 | 2025 | Immunocap |
| Glaxosmithkline, LLC. | $14.57 | 2024 | Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $14.22 | 2024 | Nuzyra |
| Janssen Biotech, INC. | $13.14 | 2023 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Macmurray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.